Cure My Disease

Don't miss your cure!

 Log in / Sign up

A simple eye-tracking test may replace button-pressing exams for pituitary tumor patients

NCT ID NCT06266949

Diagnosis Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests whether a new eye-tracking device called SONDA can accurately measure visual field loss in people with pituitary tumors. Standard visual field tests require patients to press a button when they see lights, which can be tiring and unreliable. The SONDA test instead tracks eye movements to map vision. Researchers will compare SONDA results with standard tests and check how consistent the measurements are across repeat sessions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SONDA eye-tracking visual field test
What this could lead to
If it works, this could offer a faster, easier way to detect vision loss from pituitary tumors without the need for a button-pressing response.
What could go wrong
This is a small, early-stage diagnostic study with only 30 participants. The test may not be accurate enough to replace current methods, and results may not apply to other types of vision loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a (supra)sellar tumour and healthy controls

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with a (supra)sellar tumor * Visual field loss based on the most recent SAP; False positive rate \<15%; fixation losses \<20% * Informed written consent Exclusion Criteria: * Neurological disorders * Eye disease not related to a (supra)sellar tumor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pituitary tumor are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hemianopsia Pituitary Neoplasms pituitary tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pituitary tumor Visual fields hemianopsia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UMCG

    Groningen, Provincie Groningen, 9713 GZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.